- Home
- ASMB vs THTX Comparison
ASMB vs THTX Comparison
Compare ASMB & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- THTX
- Stock Information
- Founded
- ASMB 2005
- THTX 1993
- Country
- ASMB United States
- THTX Canada
- Employees
- ASMB N/A
- THTX N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- ASMB Health Care
- THTX Health Care
- Exchange
- ASMB Nasdaq
- THTX Nasdaq
- Market Cap
- ASMB 92.1M
- THTX 93.3M
- IPO Year
- ASMB 2010
- THTX N/A
- Fundamental
- Price
- ASMB $13.61
- THTX $1.48
- Analyst Decision
- ASMB Buy
- THTX Hold
- Analyst Count
- ASMB 2
- THTX 1
- Target Price
- ASMB $35.00
- THTX N/A
- AVG Volume (30 Days)
- ASMB 25.5K
- THTX 108.7K
- Earning Date
- ASMB 03-27-2025
- THTX 02-19-2025
- Dividend Yield
- ASMB N/A
- THTX N/A
- EPS Growth
- ASMB N/A
- THTX N/A
- EPS
- ASMB N/A
- THTX N/A
- Revenue
- ASMB $28,326,000.00
- THTX $84,316,000.00
- Revenue This Year
- ASMB $282.16
- THTX $5.78
- Revenue Next Year
- ASMB N/A
- THTX $2.47
- P/E Ratio
- ASMB N/A
- THTX N/A
- Revenue Growth
- ASMB N/A
- THTX 5.75
- 52 Week Low
- ASMB $9.84
- THTX $1.08
- 52 Week High
- ASMB $19.93
- THTX $2.18
- Technical
- Relative Strength Index (RSI)
- ASMB 39.96
- THTX 36.81
- Support Level
- ASMB $13.76
- THTX $1.42
- Resistance Level
- ASMB $14.67
- THTX $1.76
- Average True Range (ATR)
- ASMB 0.72
- THTX 0.09
- MACD
- ASMB -0.09
- THTX -0.05
- Stochastic Oscillator
- ASMB 2.03
- THTX 17.63
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.